Clinical trials: Asthma, completed
Pulmonary Disease, Chronic Obstructive, Asthma COPD
Impact of a Mobile Phone and Educational Intervention
The purpose of this pilot study was to: 1. partner with African American churches to increase awareness of COPD. 2. use a community-based approach to facilitate early detection of COPD in the church setting.
- Trial name
- NCT06878898
- Testing
- Education and mobile phone text-messaging, Education only
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Kent State University
Allergy, Asthma
Sublingual Cockroach Safety in Adults With Cockroach Allergy & Perennial Allergic Rhinitis With or Without Asthma
Immunotherapy may help reduce symptoms of allergy and asthma. Problems concerning compliance and adverse events with subcutaneous allergen immunotherapy have generated interest in delivering immunotherapy sublingually (under the…
- Trial name
- SCSS (NCT00434421)
- Testing
- Glycerinated German cockroach allergenic extract
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Asthma
Efficacy and Safety of Ciclesonide in Preschool Children With Asthma (2 to 6 Years) (BY9010/M1-207)
The aim of the present study is to compare the efficacy of inhaled ciclesonide in pre-school children. Ciclesonide will be inhaled once daily, using one of three dose levels and tested versus placebo.
- Trial name
- NCT00163449
- Testing
- Ciclesonide
- Where
- 96 sites in Brazil, Germany and 7 more
- Volunteers
- 1,000 people
- Sponsor
- AstraZeneca
Asthma
Clinical Equivalence of Budesonide HFA MDI Versus Budesonide Turbuhaler in Mild to Moderate Chinese Asthma Patients
The primary objective of this study is to compare the efficacy and safety of budesonide HFA MDI 200 mcg 2 puffs BID versus budesonide DPI (Turbuhaler) 100 mcg 4 puffs BID in Chinese mild to moderate Asthma patients.
- Trial name
- NCT05152355
- Testing
- Budesonide 200 microgram/Puff, HFA MDI, Budesonide 100 microgram/Actuation Powder for Inhalation
- Where
- 13 sites in China
- Volunteers
- 270 people
- Sponsor
- Intech Biopharm Ltd.
Asthma
TRIple in Asthma hiGh strenGth vErsus Ics/Laba hs and tiotRopium (TRIGGER)
Evaluate the superiority of CHF 5993 200/6/12.5 µg pressurised metered dose inhaler (pMDI) (fixed combination of extrafine beclometasone dipropionate plus formoterol fumarate plus glycopyrronium bromide) versus CHF 1535 200/6 µg…
- Trial name
- TRIGGER (NCT02676089)
- Testing
- CHF 5993 200/6/12.5 µg, CHF 1535 200/6 µg, CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg
- Where
- 244 sites in Argentina, Belarus and 15 more
- Volunteers
- 1,437 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma
A Non- Inferiority Comparative Study Between Seretide® and Salmeterol/Fluticasone Eurofarma in Patients with Asthma
The primary objective will be to compare the formulations regarding their impact on the pulmonary function of persistent asthma patients and the secondary objective will be the clinical control of the disease's symptoms.
- Trial name
- CAINAS SF (NCT01202097)
- Testing
- Salmeterol/Fluticasone, Seretide
- Where
- 6 sites in Brazil
- Volunteers
- 334 people
- Sponsor
- Eurofarma Laboratorios S.A.
Asthma, Atopy
The JOIN Project: The Air in Diagnosis and Prevention of Asthma and Allergy
The JOIN project combines the health and indoor environment research areas to contribute in the development and validation of a new asthma diagnosis method through exhaled VOC analysis.
- Trial name
- JOIN (NCT02802891)
- Where
- Portugal
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Universidade do Porto
Asthma
C-Reactive Protein as a Predictor for Airway Hyper-Responsiveness
Background: Increased serum high sensitivity C-reactive protein (hs-CRP) has been associated with airway inflammation in asthma and may serve as a surrogate marker for the presence of airway hyper-responsiveness (AHR) in this…
- Trial name
- NCT01002144
- Testing
- blood sampling
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Rambam Health Care Campus
Moderate/Severe Asthma
NIS-observe Treatment Efficacy in Maintaining Symptoms Control in Moderate/Severe Asthma With Symbicort SMART
The primary objective of this non-interventional study is to evaluate efficacy of Symbicort® SMART treatment in adult patients with moderate to severe asthma using ACQ scores during 6 months period
- Trial name
- NCT00785733
- Where
- 44 sites in Romania
- Volunteers
- 1,182 people
- Sponsor
- AstraZeneca
Disease
Study of Medical Student Use of Templates to Document Outpatient Asthma Care in Electronic Medical Record
The purpose of the study is to measure the effectiveness of a social marketing-based medical education intervention on student use of evidence-based templates for documenting outpatient asthma care within an electronic medical…
- Trial name
- NCT01043133
- Testing
- social marketing-based medical education intervention
- Volunteers
- 155 people, healthy volunteers welcome
- Sponsor
- Uniformed Services University of the Health Sciences
Asthma
Efficacy of Omalizumab as Add on Therapy for Minority Patients With Moderate to Severe Asthma
This study will be a randomized, placebo controlled, double blind study to measure the safety and efficacy of a new, injectable asthma medication, omalizumab, in a group of minority with moderate to severe asthma who are not…
- Trial name
- NCT00180011
- Testing
- Omalizumab
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- DiMango, Emily, M.D.
Asthma
A Study to Evaluate the Onset of Relief From Methacholine-induced Bronchoconstriction With CHF1535 NEXThaler in Asthmatic Patients.
The clinical trial is designed to evaluate the non-inferiority of CHF1535 100/6 µg NEXThaler versus CHF1535 100/6 µg pMDI on the onset of relief from methacholine-induced bronchospasm, in terms of pulmonary function (i.e.
- Trial name
- NCT03108534
- Testing
- CHF1535 NEXThaler, CHF1535 pMDI
- Where
- 3 sites in United Kingdom
- Volunteers
- 65 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
This is a randomised, double-blind, parallel group, placebo-controlled study designed to evaluate the efficacy and safety of a fixed 30 mg dose of benralizumab administered subcutaneously for patients with a history of asthma…
- Trial name
- NCT03186209
- Testing
- Benralizumab
- Where
- 79 sites in China, Philippines and 2 more
- Volunteers
- 695 people
- Sponsor
- AstraZeneca
Asthma
Recombinant Human IL-4 Receptor Used in Treatment of Asthma
The purpose is to measure the effectiveness of recombinant human interleukin-4 receptor (IL-4R) in treating asthma. Asthma can be caused by the allergic response from breathing in certain irritants.
- Trial name
- NCT00017693
- Testing
- Recombinant human soluble IL-4 receptor
- Volunteers
- 62 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Asthma
Sub-Sensitivity to Long-Acting Bronchodilators (LABA)
The purpose of this study is to look at whether Advair® and SYMBICORT® have different effects on airway constriction by means of methacholine challenge testing.
- Trial name
- NCT01117116
- Testing
- fluticasone propionate and salmeterol, budesonide and formoterol
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Jewish Health
Severe Asthma
ChAracterisation of ItaliaN Severe Uncontrolled Asthmatic patieNts Key Features When Receiving Benralizumab
This is an observational, Italian multi-center, retrospective cohort study with enrollment visit on patients suffering from severe eosinophilic asthma who started benralizumab in the Sampling Program or as per normal clinical…
- Trial name
- ANANKE (NCT04272463)
- Testing
- No intervention
- Where
- 18 sites in Italy
- Volunteers
- 217 people
- Sponsor
- AstraZeneca
Asthma
A Study to Evaluate the Safety, Tolerability and Absorption to the Blood After Administration of Single and Multiple Doses of AZD8154 in Healthy Participants.
This study is a Phase 1, first in human (FiH) study, consisting of 3 parts (Part 1, Part 2, and Part 3) in healthy male and female participants of non-childbearing potential, performed at a single study center.
- Trial name
- NCT03436316
- Testing
- AZD8154
- Where
- Germany
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Acute Asthma Exacerbation
Acute Montelukast in Asthma
Patients presenting to hospital with an acute asthma exacerbation severe enough to require admission would receive full standard treatment according to British Thoracic Society guidelines in addition they would be offered the…
- Trial name
- AcMk (NCT01011452)
- Testing
- Montelukast
- Where
- United Kingdom
- Volunteers
- 87 people
- Sponsor
- University of East Anglia
Asthma
Effect of Omalizumab in Patients With Severe Persistent Non-atopic Uncontrolled Asthma
This study will assess the change in the expression of FcεRI receptors of blood basophils and dendritic cells after 16 weeks of treatment with omalizumab as compared with placebo, in adult patients with non-atopic severe…
- Trial name
- NATAIR (NCT01007149)
- Testing
- omalizumab
- Where
- 10 sites in France
- Volunteers
- 79 people
- Sponsor
- Novartis Pharmaceuticals
Delirium, Confusion
Improving Safety of Diagnosis and Therapy in the Inpatient Setting
To improve the safety of diagnosis and therapy for a set of conditions and undifferentiated symptoms for hospitalized patients, the investigators will employ a set of methods and tools from the disciplines of systems engineering…
- Conditions
- Delirium, Confusion, Mental Status Change, Back Pain
- Trial name
- PSLL2-0 (NCT04393909)
- Testing
- Diagnostic Uncertainty Educational Curriculum, Diagnostic Timeout, Patient Diagnostic (Dx) Questionnaire
- Where
- United States
- Volunteers
- 700 people
- Sponsor
- Brigham and Women's Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.